Skip Ribbon Commands
Skip to main content
Clin Assoc Prof Tham Chee Kian

Clin Assoc Prof Tham Chee Kian

MBBS (S’pore), MMed (Internal Medicine), MRCP (UK)

Deputy Head and Senior Consultant

Deputy Chairman & Senior Consultant

National Cancer Centre Singapore

Specialty: Medical Oncology

Clinical Interest: Neuro-Oncology, Hepato-Pancreato-Biliary, Gastrointestinal

Clinical Appointments

  • Deputy Chairman & Senior Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Assistant Professor


Dr Tham Chee Kian is the Deputy Chairman and Senior Consultant at the Division of Medical Oncology at the National Cancer Centre Singapore (NCCS). His subspecialty interest is in neuro-oncology and gastrointestinal oncology. He also holds an academic appointment as Clinical Associate Professor with the Duke-NUS Medical School.


  • Master of Medicine (Internal Medicine), National University of Singapore, 2005
  • MRCP (UK), 2005
  • MBBS Singapore, National University of Singapore, 2002

Professional Appointments and Committee Memberships

Fellowship of the Academy of Medicine, Singapore (FAMS)
Deputy Chairman, Chapter of Medical Oncologists, College of Physicians Singapore
2021 - Current

Singapore Society of Oncology
2007 - Current

Society of Neuro-Oncology
2009 - 2016

American Society of Clinical Oncology
2007 - 2018


  • Education Leader Award, SingHealth Medicine Academic Program (ACP), 2021
  • SingHealth GCEO Excellence Awards: Outstanding Educator Award, 2019
  • SingHealth Quality Service Award, 2010, 2011, 2018, 2021

Research Interests


  1. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer. Tham CK, Chew M, Soong R, Lim J, Ang M, Tang C, Zhao Y, Ong SY, Liu Y
  2. Serum methylation levels of TAC1. SEPT9 and EYA4 as diagnostic markers for early colorectal cancers: a pilot study. Liu Y, Tham CK, Ong SY, Ho KS, Lim JF, Chew MH, Lim CK, Zhao Y, Tang CL, Eu KW
  3. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. Chong DQ, Toh XY, Ho IA, Sia KC, Newman JP, Yulyana Y, Ng WH, Lai SH, Ho MM, Dinesh N, Tham CK*, Lam PY*
  4. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. Van Cutsem E, Li CP, Nowara E, Aprile G, Moore M, Federowicz I, Van Laethem JL, Hsu C, Tham CK, Stemmer SM, Lipp R, Zeaiter A, Fittipaldo A, Csutor Z, Klughammer B, Meng X, Ciuleanu T.
  5. Methylation of Serum SST gene is an Independent Prognostic Marker in Colorectal CancerYanqun Liu, Min Hoe Chew, Chee Kian Tham, Choong Leong Tang, Simon YK Ong, Yi Zhao
  6. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine–Induced Hand-Foot Syndrome: A Randomized Clinical Trial. YS Yap, LL Kwok, N Syn, WY Chay, JWK Chia, CK Tham, NS Wong, HC Toh, WH Koo, M Loh, RCH Ng, SP Choo, RTS Chuan
  7. Early outcomes of a National Cancer Cetnre’s Strategy against COVID-19 executed through a Disease Outbreak Response Taskforce. JW Kwek, JJ Chan, R Kanesvaran, MLC Wang, PSH Neo, CS Chia, CK Tham, LST Chew, HK Tan, SP Yap, RA Dent, WYK Hwang, ST Lim
  8. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC) WM Tai; WP Yong; C Lim; LS Low; CK Tham; TS Koh; QS Ng; WW Wang; L Z Wang; S. Hartano; CH Thng; H Huynh; KT Lim; HC Toh; BC Goh; SP Choo
  9. Gastrointestinal Stromal Tumour in the Elderly CK Tham, DYH Poon, HH Li, MH Tan, SP Choo, KF Foo
  10. Gefitinib in combination with gemcitabine and carboplatin in never-smokers with non-small cell lung carcinoma: a retrospective analysis. CK Tham, SP Choo, WT Lim, CK Toh, SS Leong, SH Tan, HH Li, EH Tan

Research Trials

  • ABT-414 alone or ABT-414 plus temozolomide vs. lomustine or temozolomide for recurrent glioblastoma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC protocol 1410-BTG)
    2016 - 2020 Site Principal Investigator
  • A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1).
    2016 - 2020 Site Principal In-vestigator
  • A phase I/II, open-label, multi-center study of the safety and efficacy of BLZ945 as single agent and in combination with PDR001 in adult patients with advanced solid tumors (CBLZ945X2101).
    2020 - 2021 Site Principal In-vestigator